Abstract
Protein-protein interactions are increasingly becoming drug targets. This is understandable, since they are crucial at all levels of cellular expression and growth. In practice, targeting specific disease-related interactions has proven difficult, with success varying with specific complexes. Here, we take a Systems Biology approach to targeting protein-protein interactions. Below, we first briefly review drug discovery targeted at protein-protein interactions; we classify protein-protein complexes with respect to their types of interactions and their roles in cellular function and as being targets in drug design; we describe the properties of the interfaces as related to drug design, focusing on hot spots and surface cavities; and finally, in particular, we cast the interactions into the cellular network system, highlighting the challenge of partially targeting multiple interactions in the networks as compared to hitting a specific proteinprotein interaction target. The challenge we now face is how to pick the targets and how to improve the efficiency of designed partiallyspecific multi-target drugs that would block parallel pathways in the network.
Keywords: hot regions, Drug Design, allosteric site, G protein-coupled receptors, FK1012
Current Topics in Medicinal Chemistry
Title: Towards Drugs Targeting Multiple Proteins in a Systems Biology Approach
Volume: 7 Issue: 10
Author(s): O. Keskin, A. Gursoy, B. Ma and R. Nussinov
Affiliation:
Keywords: hot regions, Drug Design, allosteric site, G protein-coupled receptors, FK1012
Abstract: Protein-protein interactions are increasingly becoming drug targets. This is understandable, since they are crucial at all levels of cellular expression and growth. In practice, targeting specific disease-related interactions has proven difficult, with success varying with specific complexes. Here, we take a Systems Biology approach to targeting protein-protein interactions. Below, we first briefly review drug discovery targeted at protein-protein interactions; we classify protein-protein complexes with respect to their types of interactions and their roles in cellular function and as being targets in drug design; we describe the properties of the interfaces as related to drug design, focusing on hot spots and surface cavities; and finally, in particular, we cast the interactions into the cellular network system, highlighting the challenge of partially targeting multiple interactions in the networks as compared to hitting a specific proteinprotein interaction target. The challenge we now face is how to pick the targets and how to improve the efficiency of designed partiallyspecific multi-target drugs that would block parallel pathways in the network.
Export Options
About this article
Cite this article as:
Keskin O., Gursoy A., Ma B. and Nussinov R., Towards Drugs Targeting Multiple Proteins in a Systems Biology Approach, Current Topics in Medicinal Chemistry 2007; 7 (10) . https://dx.doi.org/10.2174/156802607780906690
DOI https://dx.doi.org/10.2174/156802607780906690 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Pharmacology of Cyclic Nucleotide-Gated Channels: Emerging from the Darkness
Current Pharmaceutical Design Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia
Current Pharmaceutical Design Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Identification of Functional Peptides from Natural and Synthetic Products on Their Anticancer Activities by Tumor Targeting
Current Medicinal Chemistry Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation
Current Drug Targets The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry